LGVN Longeveron Corporation Company Total Asset Base

LGVN (Longeveron Inc) - company brandmark

Longeveron Inc. (LGVN) specializes in the development of Lomecel-B, leveraging test results for heart hypoplasia and Alzheimer's disease. Its operations are protected by US laws, which eliminates geopolitical risks. The historical price action of total assets, reaching 16.12, is illustrated below. The team consists of elite biologists retained through generous stock options and grants to combat age-related pathologies.

Longeveron Corp (LGVN) - Company Total Assets from 07/04/2022 to 10/30/2026

Financial and market metric breakdowns for Longeveron Corp (LGVN)

- stock quotes and analyst forecast:
Share Price longeveron.com|LGVN - Price Target Chart
- market capitalization data:
Market Capitalization Longeveron Corporation|LGVN - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Price of a Share Longeveron|LGVN - Book Capitalization|Market-to-Book Ratio longeveron.com|LGVN - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Longeveron Inc.|LGVN - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Longeveron Corporation|LGVN - Company Aggregate Debts|Debts to Book Value Longeveron Corporation|LGVN - Company Long-Term Debt|Company Short-Term Debt Longeveron|Quick Liquidity longeveron.com
- earnings and valuation multiples indicators:
LGVN - Company Net Income
Fundamental valuation:LGVN longeveron.com
Core merchandise of Longeveron Inc.

Institutional capital assesses the attractiveness of Longeveron Inc. (LGVN) based on the volume of resources required to complete clinical trials, as the success of cell therapy depends on treatment efficacy rather than market cycles. The dynamics of the company's total resources, calculated inversely via ROA, allow for the identification of accounting anomalies and an assessment of the asset's real material base to mitigate delisting risks.

Main competitors

Total Business Assets MESO|Aggregate Company Assets Lineage Cell Therapeutics, Inc.|Surrozen Inc (SRZN) - Company Total Asset Base|Cumulative Company Assets CCEL (Cryo-Cell International)|Aggregate Business Assets FBLG|Company Total Assets BRTX (BioRestorative Therapies, Inc.)|Creative Medical Technology Holdings, Inc. (CELZ) - Company Assets